JPRN-jRCT1030220731尚未招募1 期
A Phase I Clinical Study of Dose Escalation in Stereotactic Body Radiotherapy for Hepatocellular Carcinoma/Metastatic Liver Tumors
Yamashita Hideomi0 个研究点目标入组 36 人开始时间: 2023年3月25日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •a) Patients with pathologically or clinically (by dynamic contrast-enhanced CT or EOB-MRI of the liver) diagnosed primary or recurrent hepatocellular carcinoma or localized metastatic liver tumor who are not candidates for radical treatment (liver resection, RFA, liver transplantation) and will receive stereotactic body radiation therapy.
- •b) Patients whose pre-enrollment treatment plan meets the dose constraints.
- •c) Patients with Child-pugh classification grade A or B.
- •d) Performance status (PS) of 0-2.
- •e) Over 18 years old.
- •f) Patients who have given their written consent to participate in the study.
排除标准
- •a) Patients who do not consent to participate in the study.
- •b) With lymph node metastasis or distant metastasis in other organs.
- •c) With a history of prior radiotherapy to liver.
- •d) With WBC <2,000/mm3, HB <8g/dl, or Plt <50.000/mm3.
- •e) Patients participating in other clinical trials that may affect the conduct or outcome of this study.
- •f) Other patients who are deemed inappropriate to participate in this study by the investigator or co-investigaters.
研究者
相似试验
进行中（未招募）
1 期
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia - Vorinostat in childreRelapsed of progressive solid tumor, lymphoma, or leukemia in children and adolescents aage 3-18 yearsMedDRA version: 18.0 Level: HLGT Classification code 10024324 Term: Leukaemias System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 18.0 Level: PT Classification code 10025310 Term: Lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-005537-11-DEniversity Hospital Heidelberg50
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000054936EUCTR2012-002888-10-GBPCI Biotech AS68
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 20.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864EUCTR2012-002888-10-FRPCI Biotech AS61
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 19.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864EUCTR2012-002888-10-LTPCI Biotech AS61
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable locally advanced cholangiocarcinomasMedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2012-002888-10-DEPCI Biotech AS24